To ascertain whether prostaglandins (PG) may play a role in the secretion of glucagon and in an attempt to elucidate the conflicting observations on the effects of PG on insulin release, the isolated intact rat 5
ancreas was perfused with solutions containing 1.1 x 10sg to 1.8 x lo-M PGE2. In the presence of 5.6 mM glucose significant increments in portal venous effluent levels of glucagon and insulin were observed in response to minimal concentrations of 2.8 x 10-8 and 1.4 x lo-%l PGE2, respectively; a dose-response relationship was evident for both hormones at higher concentrations of PGE2. When administered over 60 seconds, 1.4 x lo-6M PGE2 resulted in a significant increase in glucagon levels within 24 seconds and in insulin within 48 seconds. Ten-minute perfusions of 1.4 x 10m6M PGE2 elicited biphasic release of both islet hormones; Phase I glucagon release preceded that of insulin. Both phases of the biphasic glucagon and insulin release which occurred in response to 15-minute perfusions of 10 mM arginine were augmented by PGE2. cagon and These observations indicate that PGE2 can evoke gluinsulin release at concentrations close to those observed by others in the extracts of rat pancreas. We conclude that PG may be involved in the regulation of secretion of glucagon and insulin and may mediate and/or modify the pancreatic islet hormone response to other secretagogues. 
INTRODUCTION

MATERIALS AND METHODS
Wale, albino Sprague-Dawley rats weighing 250-300 g were fed with Purina rat chow.
Food was withdrawn 16-18 hours prior to the beginning of the experiments.
The animals were anesthetized with sodium pentabarbital, 50 mg/kg body weight, injected intraperitoneally. The surgical technique employed for the removal of the pancreas'was a modification of that described by Sussman et al. (13) . The pancreas was dissected free from all surrounding structures; its connections to a short segment of the duodenum and its vasculature were left intact. All vessels not supplying the pancreas were ligated. The segment of the abdominal aorta from which the celiac and the superior mesenteric arteries originate was cannulated in a retrograde fashion and perfused with an oxygenated buffer medium. Another cannula was placed in the portal vein to collect the effluent from the pancreas. A third cannula was inserted in the duodenum to ascertain the free flow of exocrine pancreatic secretions and to relieve pressure in the pancreatic duct.
To retain correct anatomical position of the vasculature, the pancreas was affixed on a small platform using ligatures which had been placed on the three cannulae.
The surgical procedure was completed within 60-80 minutes.
During this period the pancreas was being perfused either by the animal's own circulation or by the oxygenated buffer medium so that the oxygen supply was adequate at all times.
The isolated pancreas was suspended in a physiological buffer medium contained in a perfusion chamber.
The chamber was placed in a perfusion apparatus which was a modification of that reported by Sussman et al. (13) .
The ambient temperature was 37O C. The system contained four independent perfusion channels which merged into a manifold to which the aortic cannula was connected.
With the use of this manifold-regulated multichannel system, within a fraction of a second any one of the four perfusion solutions could be diverted to perfuse the pancreas, while the remaining three solutions were being recirculated in an "idle"mode to permit continuous oxygenation and to prevent delays in changing buffer solutions. The flow rate was kept constant at 2.5 ml/min in all channels by using a multichannel roller pump. The aortic perfusion pressure was monitored at all times; the pressure ranged between 30-50 mm Hg and had a pulse amplitude of 2-4 mm Hg.
The artificial perfusion medium had the following composition (mmol/l): NaCl 118.5, KC1 3.5, MgSO4.7H20 1.0, KH2PO4 1.2, CaC12.2H20 1.25, and NaHC03 24.9. Dextran, average mol. weight 70,000 (Pharmacia), 40 g/l, and bovine serum albumin (Miles Labs.), 2 g/l, were added to maintain a physiological oncotic pressure and to minimize adhesion of hormones to glassware. After equilibration with 95% 02 and 5% CO2 the oxygen tension of the solution was around 400-450 mm Hg and the pH was 7.4. In all experiments the perfusion solutions contained 5.6 mM D-glucose at all times.
L-arginine monohydrochloride (ICN) and PGE2 (Upjohn Co.) were dissolved directly in the perfusion medium.
Following the attachment of the pancreas to the perfusion system, an equilibration period of 30 minutes preceded the experiments. All experiments were completed within 60-90 minutes. At the end of each experimental period the functional integrity of the pancreas was ascertained by assessing the glucagon and insulin secretory response to l-minute perfusions of 10 mM arginine.
The portal venous effluent was collected in 12-60 second fractions. The samples were stored at -20' C until the time of hormone assays.
Portal venous effluent levels of immunoreactive glucagon were measured by a "double-antibody" method using antiglucagon serum G9-I which has a negligible cross-reactivity with glucagon-like materials present in extracts of intestines (14). Immunoreactive insulin was determined by a modification of the method described by Morgan and Lazarow (15) ; rat insulin (Novo, Denmark) was used as standards.
The statistical significance of differences between observed values was determined by paired t-test (16).
RESULTS
Solutions of PGE2 were prepared in seven different concentrations ranging from 1.1 x lo-9M to 1.8 x lo-5M. Each solution was administered to 4 pancreases over successive 2-minute periods, separated by lo-minute rest periods during which the organs were perfused with buffer alone. The results are shown in Fig. 1 . At PGE2 concentrations of 2.8 x lo-8M or greater, the mean maximal effluent level of glucagon attained during the 5 minutes after the beginning of each perfusion period was significantly greater than the level observed during the preceding basal period. Increases in insulin levels occurred consistently in response to PGE2 at 1.4 x 10m7M or greater. A dose-response relationship was observed for both islet hormones. The rapidity of glucagon and insulin secretory res ! onses was investigated by.perfusing 6 pancreases with PGE2 1.4 x IO' M over 60 seconds and collecting 12-second effluent fractions over 180 seconds (Fig.  2) . The first significant increase above basal levels in glucagon occurred within 24 seconds at a time when no increases in insulin levels were discernable. If corrected for the 10 seconds which elapsed for the secretagogue to reach the pancreas, this response time would be reduced to 14 seconds. The first significant increment in insulin was observed at 48 seconds. The mean maximal responses in glucagon and insulin were 48 and 72 seconds, respectively. The patterns of PG-induced secretion of glucagon and insulin were determined by perfusing 5 pancreases with 1.4 x 10q6M PGE2 over 10 minutes (Fig. 3) .
The mean effluent glucagon increased from a basal value of 91 + 12 pg/ml to a maximal level of 838 + 148 pg/ml within 1 minute.
Mean glucagon decreased to around 300 pg/ml by the third minute and was sustained at this level until the termination of the perfusion of PGE2. A similar biphasic release was observed also in insulin.
The mean maximal level of 37 + 18 pU/ml was attained at 2 minutes.
The Phase I release was completed by the fourth minute. Thereafter insulin levels remained significantly elevated above the basal levels throughout the remainder of the period of PG perfusion. The effects of PG upon the release of pancreatic hormones in response to another secretagogue were examined. Each pancreas was perfused with 10 mM solutions of arginine over two 15-minute periods. For 10 minutes preceding and during one of these periods of arginine administration the perfusate contained PGE2, 2.8 x lo-7M. The test periods were separated by 15-minute rest periods and were arranged randomly. Arginine evoked the expected biphasic increases in the levels of glucagon and insulin; Phase I release dissipated within 4-5 minutes. Phase I and Phase II hormonal responses were computed as incremental areas under the response curve (Table 1) . PGEI, augmented both phases of glucagon and of insulin release induced by arginine.
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Mean : S.E.M. incremental insulin to 15-minute Table 1 response areas in glucagon and perfusioes of 10 mM arginine with and without 2.8 x 10-/M PGE2 (N=6) 
DISCUSSION
The results of our studies indicate that administered PGE2 is a potent secretagogue of glucagon as well as of insulin in the isolated rat pancreas.
The physiological significance of these observations remains to be established. Karim et al. have reported that the concentration of PGE2 in the rat pancreas is 18.2 rig/g wet tissue (17). The lowest perfusate concentrations of PGE2 at which we have observed significant increases in glucagon and insulin release approach those tissue levels. These findings are consistent with the hypothesis that prostaglandin synthesis within the pancreas may be one of the mechanisms regulating the secretion of glucagon and insulin.
As demonstrated in the studies reported here for arginine, the secretion of islet hormones in response to a variety of stimuli is biphasic. The release of glucagon and insulin induced by administered PGE2 was also biphasic. Thus endogenous PG may play a role as mediators of biphasic islet hormone release in response to certain stimuli.
PG-induced glucagon release preceded that of insulin. We have reported that such sequential release of glucagon and insulin occurs in response to a variety of stimuli common to both hormones (18). Glucagon stimulates insulin release when administered in pharmacological amounts (19). Thus prior release of glucagon observed in our studies may have a physiological significance in the secretion of insulin which follows. However, the analysis of our results failed to reveal any correlation between the dynamics or the magnitudes of glucagon release (18). Therefore, under the conditions which prevailed in our studies, the antecedent release of glucagon does not appear to be the principal mediator of insulin release. On the other hand, at times when both islet hormones are being secreted, a role for endogenous glucagon as a modifier of insulin release has not been ruled out.
Among prostaglandins, PGEZ does not appear to be unique in stimulating the release of glucagon and insulin. Our preliminary studies indicate that PGEl and PGFza have similar effects on both islet hormones (20). The obversations made by others (3) (4) (5) on the stimulation of insulin release by PGEl are in support of our findings.
In conclusion, prostaglandins may be involved in the regulation of secretion of glucagon and insulin and may mediate and/or modify the pancreatic islet hormone response to other secretagogues.
